Medical Affairs Reputations (EU5) [NSCLC]
Survey of oncologists shows your medical affairs team may not be reaching out often enough
If your medical affairs team isn’t getting an enthusiastic response from doctors, it may be time to step things up. Our survey of 150 medical oncologists shows that they’re hungry for information, and feel that EU5-based medical affairs teams for leading NSCLC treatments should be contacting them more often. With several teams competing closely, the right approach could make all the difference.
Find out how often doctors want to hear from you, and what else you can do to move your team ahead of its closest rivals in Medical Affairs Reputations: NSCLC (EU5).
Comparing 10 major NSCLC treatments from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck KGaA, Merck Sharp & Dohme, Novartis, Pfizer, and Roche, this detailed report reveals:
Top Takeaways
Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 10 medical affairs teams—answering important questions like:
What do doctors need?
About FirstWord
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
If your medical affairs team isn’t getting an enthusiastic response from doctors, it may be time to step things up. Our survey of 150 medical oncologists shows that they’re hungry for information, and feel that EU5-based medical affairs teams for leading NSCLC treatments should be contacting them more often. With several teams competing closely, the right approach could make all the difference.
Find out how often doctors want to hear from you, and what else you can do to move your team ahead of its closest rivals in Medical Affairs Reputations: NSCLC (EU5).
Comparing 10 major NSCLC treatments from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck KGaA, Merck Sharp & Dohme, Novartis, Pfizer, and Roche, this detailed report reveals:
- How oncologists rate your team overall, and on 12 key medical affairs services.
- Which medical affairs services are most important.
- How, and how often oncologists want to meet with your team.
- What you can do to improve your medical affairs services.
Top Takeaways
- You may not be reaching out often enough: Survey results show that teams aren’t necessarily contacting doctors as often as they’d like. Find out how often they want to hear from your team.
- One team has a clear lead: Rated for overall quality of interactions, the leading team is more than four points ahead. Farther down the pack there are at least three extremely close races.
- Solid performances all around: EdgeMap performance ratings show moderately good scores for all teams, especially in the two most important areas. The top team leads in all but one area.
- Satisfaction scores are modest: EdgeMap satisfaction scores run from just above neutral to somewhat satisfied. The same two teams lead in every area, sometimes by a significant margin.
- Doctors want actionable information: Four of the top five roles for medical affairs teams revolve around providing information doctors can use to make better treatment decisions.
- One key area needs improvement: Need gap analysis reveals that five of the ten surveyed teams must improve the same medical affairs service to boost their satisfaction scores.
- ....
- ....
- ...
- Avastin (bevacizumab; Roche)
- Cyramza (ramucirumab; Eli Lilly)
- Giotrif (afatinib; Boehringer Ingelheim)
- Iressa (gefitinib; AstraZeneca)
- Keytruda (pembrolizumab; Merck Sharp & Dohme)
- Opdivo (nivolumab; Bristol-Myers Squibb)
- Tagrisso (osimertinib; AstraZeneca)
- Tarceva (erlotinib; Roche)
- Xalkori (crizotinib; Pfizer/Merck Group)
- Zykadia (ceritinib; Novartis)
Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 10 medical affairs teams—answering important questions like:
What do doctors need?
- How, and how often are they using your medical affairs team?
- What services do they consider most important?
- How often should you contact them? What channels are best?
- How memorable are your team’s interactions with doctors?
- How do doctors rank your team for performance and satisfaction in 12 key areas?
- How does your team compare to the competition—in each area, and overall?
- Are you delivering the services that are most important to doctors?
- Where do you need to improve?
- How can your team enhance its services?
- Based on Interviews with Practicing Doctors
- All respondents:
- Have been practicing for between 3 and 35 years
- See at least 5 patients with NSCLC in a typical month
- Devote at least 50% of their time to direct patient care
- Have interacted with at least one listed product’s medical affairs team in the past 6 months.
- We conducted the survey between February 2nd and 8th, 2017.
About FirstWord
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
1. OBJECTIVES, SURVEY METHODOLOGY AND SAMPLING, PRODUCTS INCLUDED IN THE SURVEY, EXECUTIVE SUMMARY
2. CURRENT STATUS OF INTERACTIONS WITH DIFFERENT MEDICAL AFFAIRS TEAMS
2.1 Interactions in the past 6 months with Medical Affairs teams for each product
2.2 Current frequency of interactions with medical affair teams for each product
3. COMPETITIVE EVALUATION OF MEDICAL AFFAIRS TEAMS PERFORMANCE ON VARIOUS ATTRIBUTES
3.1 Evaluation of overall quality of interactions with Medical Affairs teams for each product
3.2 Attribute importance of Medical Affairs teams roles to physicians’ practice
3.3 EdgeMap analysis – Competitive evaluation on Medical Affairs teams performance on attributes
3.4 Competitive evaluation of physicians satisfaction of interaction with Medical Affairs teams
3.5 Need-Gap analysis by product
4. PREFERRED INTERACTION MEDIA, FREQUENCY, AND SUGGESTIONS FOR IMPROVEMENT
4.1 Preferred interaction media and frequency, and suggestions for improvement
5. APPENDIX
2. CURRENT STATUS OF INTERACTIONS WITH DIFFERENT MEDICAL AFFAIRS TEAMS
2.1 Interactions in the past 6 months with Medical Affairs teams for each product
2.2 Current frequency of interactions with medical affair teams for each product
3. COMPETITIVE EVALUATION OF MEDICAL AFFAIRS TEAMS PERFORMANCE ON VARIOUS ATTRIBUTES
3.1 Evaluation of overall quality of interactions with Medical Affairs teams for each product
3.2 Attribute importance of Medical Affairs teams roles to physicians’ practice
3.3 EdgeMap analysis – Competitive evaluation on Medical Affairs teams performance on attributes
3.4 Competitive evaluation of physicians satisfaction of interaction with Medical Affairs teams
3.5 Need-Gap analysis by product
4. PREFERRED INTERACTION MEDIA, FREQUENCY, AND SUGGESTIONS FOR IMPROVEMENT
4.1 Preferred interaction media and frequency, and suggestions for improvement
5. APPENDIX
